Here you go. A mixed bag of studies, articles, abstracts. posters, info, mentions. It's about 1/2 of what I found in an hour. If I had 8 hours, I could post about 10 times more. Even more interest out there than I thought.
https://www.lu.se/search?tab=undefined&query=Eltoprazine
2017 International Congress of
Parkinson’s Disease and Movement Disorders
VANCOUVER
June 4–8, 2017
British Columbia, Canada
MDS-0417-480
Late-Breaking Abstracts,
MDS Study Group Abstracts and
Guided Poster Tour Information
Conclusions: Results suggest that combination of L-DOPA plus preladenant and eltoprazine could be a promising
pharmacological strategy to ameliorate L-DOPA efficacy and prevent the onset of L-DOPA-induced dyskinesia in
PD.
http://www.mdscongress2017.org/Congress-2017-...ASGGPT.pdf
6th Mediterranean Neuroscience Society Conference 2017
MALTA MNS2017
Radisson BLU, St Julian’s, Malta, June 12 – 15, 2017
A NOVEL THERAPEUTIC STRATEGY FOR THE PREVENTION OF THE ONSET OF DYSKINESIA IN THE THERAPY OF PARKINSON’S DISEASE
http://www.mnsmeeting2017.com/wp-content/uplo...NS2017.pdf
https://issuu.com/maltachamberofscientists/do...compressed
Advances in Management of
Parkinson’s Disease and Essential Tremor
Melita Petrossian, MD
Medical Director, Pacific Movement Disorders Center
Pacific Neuroscience Institute
Providence Saint John’s Health Center
September 23, 2017
http://www.pacificneuroscienceinstitute.org/a...tation.pdf
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
2016 Apr;31
CONCLUSIONS:
Our results suggest a promising nondopaminergic pharmacological strategy for the treatment of dyskinesia in PD. © 2016 International Parkinson and Movement Disorder Society.
https://www.ncbi.nlm.nih.gov/pubmed/26871939
Levodopa-induced dyskinesia: Clinical features, pathophysiology, and medical managemen
Date of Web Publication 10-Aug-2017
http://www.annalsofian.org/article.asp?issn=0...ast=Pandey
Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease
Date of Web Publication 25-Jul-2017
http://www.cmj.org/article.asp?issn=0366-6999...;aulast=Du
Journal -Expert Opinion on Investigational Drugs
Volume 26, 2017 - Issue 7
Received 03 Feb 2017, Accepted 18 May 2017, Accepted author version posted online: 24 May 2017, Published online: 01 Jun 2017
Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias
Expert opinion: LIDs are sustained by complex molecular and neurobiological mechanisms that are difficult to disentangle or target, unless one or more prevalent mechanisms are identified. In this context, the role of the serotonergic system and mGluR5 glutamate receptors seem to stand out. Interesting results have been obtained, for example, with partial 5-HT1A/5-HT1B receptor agonist eltoprazine and mGluR5 negative allosteric modulator dipraglurant. Confirmation of these results through large-scale, Phase III clinical trials will be needed, to obtain new pharmacological tools that may be used to optimize the treatment of PD patients with motor complications.
http://www.tandfonline.com/doi/abs/10.1080/13...ode=ieid20
Eltoprazine counteracts L-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
05 February 2015
https://academic.oup.com/brain/article/138/4/963/280283
Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications
12 September 2017
The clinical implications of these 5-HT adaptive changes could underlie the efficacy of drugs acting on 5-HT neurotransmission to reduce the severity of dyskinesia. Although in animal models of the disease several drugs acting on 5-HT1A/1C or 5-HT1B receptors decrease the expression of L-DOPA-induced dyskinesia (Miguelez et al., 2013), translational extrapolation to the clinic has been less positive. So far, only two drugs have been proven to be clinically efficient in treating dyskinesia. These are eltoprazine, a 5-HT1A/B receptor agonist (Bomasang-Layno et al., 2015; Svenningsson et al., 2015), and buspirone, a partial agonist of the 5-HT1A receptor, which discretely ameliorates dyskinesia (Politis et al., 2014). In general, 5-HT compounds have been demonstrated to be less efficacious than expected, probably because the existing theories about 5-HT and DA interaction, especially in the striatum, are too simplistic.
https://www.frontiersin.org/articles/10.3389/...00274/full
Trouble with the happy hormone: the biological basis of dyskinesia
Nov 6, 2017
One of the latest ideas is to target the serotonin-producing cells to trick them into thinking they are releasing too much serotonin. This could slow the release of hijacked, dopamine mixed packages, and prevent the levels of dopamine in the synapse increasing further. An early (stage 2a) clinical trial of a drug called Eltoprazine has already shown promise for this approach. But further research is still needed to develop these medications before they are made available.
https://medium.com/parkinsons-uk/trouble-with...aac1bd5ad7
Induce levodopa of 5 - HT1A / B agonist ( eltoprazine ) Developmental dyskinesia inhibitory effect
https://translate.google.com/translate?hl=en&...rev=search
The 5-HT1A/1B-receptor agonist eltoprazine increases both catecholamine release in the prefrontal cortex and dopamine release in the nucleus accumbens and decreases motivation for reward and "waiting" impulsivity, but increases "stopping" impulsivity.
2017 Jan 5
https://www.ncbi.nlm.nih.gov/pubmed/27866999
Pharmacological Advances in the Treatment of Schizophrenia
Published online: May 16, 2017
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
https://clinicaltrials.gov/ct2/show/record/NCT01266174
https://www.lu.se/search?tab=undefined&query=Eltoprazine
2017 International Congress of
Parkinson’s Disease and Movement Disorders
VANCOUVER
June 4–8, 2017
British Columbia, Canada
MDS-0417-480
Late-Breaking Abstracts,
MDS Study Group Abstracts and
Guided Poster Tour Information
Conclusions: Results suggest that combination of L-DOPA plus preladenant and eltoprazine could be a promising
pharmacological strategy to ameliorate L-DOPA efficacy and prevent the onset of L-DOPA-induced dyskinesia in
PD.
http://www.mdscongress2017.org/Congress-2017-...ASGGPT.pdf
6th Mediterranean Neuroscience Society Conference 2017
MALTA MNS2017
Radisson BLU, St Julian’s, Malta, June 12 – 15, 2017
A NOVEL THERAPEUTIC STRATEGY FOR THE PREVENTION OF THE ONSET OF DYSKINESIA IN THE THERAPY OF PARKINSON’S DISEASE
http://www.mnsmeeting2017.com/wp-content/uplo...NS2017.pdf
https://issuu.com/maltachamberofscientists/do...compressed
Advances in Management of
Parkinson’s Disease and Essential Tremor
Melita Petrossian, MD
Medical Director, Pacific Movement Disorders Center
Pacific Neuroscience Institute
Providence Saint John’s Health Center
September 23, 2017
http://www.pacificneuroscienceinstitute.org/a...tation.pdf
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
2016 Apr;31
CONCLUSIONS:
Our results suggest a promising nondopaminergic pharmacological strategy for the treatment of dyskinesia in PD. © 2016 International Parkinson and Movement Disorder Society.
https://www.ncbi.nlm.nih.gov/pubmed/26871939
Levodopa-induced dyskinesia: Clinical features, pathophysiology, and medical managemen
Date of Web Publication 10-Aug-2017
http://www.annalsofian.org/article.asp?issn=0...ast=Pandey
Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease
Date of Web Publication 25-Jul-2017
http://www.cmj.org/article.asp?issn=0366-6999...;aulast=Du
Journal -Expert Opinion on Investigational Drugs
Volume 26, 2017 - Issue 7
Received 03 Feb 2017, Accepted 18 May 2017, Accepted author version posted online: 24 May 2017, Published online: 01 Jun 2017
Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias
Expert opinion: LIDs are sustained by complex molecular and neurobiological mechanisms that are difficult to disentangle or target, unless one or more prevalent mechanisms are identified. In this context, the role of the serotonergic system and mGluR5 glutamate receptors seem to stand out. Interesting results have been obtained, for example, with partial 5-HT1A/5-HT1B receptor agonist eltoprazine and mGluR5 negative allosteric modulator dipraglurant. Confirmation of these results through large-scale, Phase III clinical trials will be needed, to obtain new pharmacological tools that may be used to optimize the treatment of PD patients with motor complications.
http://www.tandfonline.com/doi/abs/10.1080/13...ode=ieid20
Eltoprazine counteracts L-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
05 February 2015
https://academic.oup.com/brain/article/138/4/963/280283
Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications
12 September 2017
The clinical implications of these 5-HT adaptive changes could underlie the efficacy of drugs acting on 5-HT neurotransmission to reduce the severity of dyskinesia. Although in animal models of the disease several drugs acting on 5-HT1A/1C or 5-HT1B receptors decrease the expression of L-DOPA-induced dyskinesia (Miguelez et al., 2013), translational extrapolation to the clinic has been less positive. So far, only two drugs have been proven to be clinically efficient in treating dyskinesia. These are eltoprazine, a 5-HT1A/B receptor agonist (Bomasang-Layno et al., 2015; Svenningsson et al., 2015), and buspirone, a partial agonist of the 5-HT1A receptor, which discretely ameliorates dyskinesia (Politis et al., 2014). In general, 5-HT compounds have been demonstrated to be less efficacious than expected, probably because the existing theories about 5-HT and DA interaction, especially in the striatum, are too simplistic.
https://www.frontiersin.org/articles/10.3389/...00274/full
Trouble with the happy hormone: the biological basis of dyskinesia
Nov 6, 2017
One of the latest ideas is to target the serotonin-producing cells to trick them into thinking they are releasing too much serotonin. This could slow the release of hijacked, dopamine mixed packages, and prevent the levels of dopamine in the synapse increasing further. An early (stage 2a) clinical trial of a drug called Eltoprazine has already shown promise for this approach. But further research is still needed to develop these medications before they are made available.
https://medium.com/parkinsons-uk/trouble-with...aac1bd5ad7
Induce levodopa of 5 - HT1A / B agonist ( eltoprazine ) Developmental dyskinesia inhibitory effect
https://translate.google.com/translate?hl=en&...rev=search
The 5-HT1A/1B-receptor agonist eltoprazine increases both catecholamine release in the prefrontal cortex and dopamine release in the nucleus accumbens and decreases motivation for reward and "waiting" impulsivity, but increases "stopping" impulsivity.
2017 Jan 5
https://www.ncbi.nlm.nih.gov/pubmed/27866999
Pharmacological Advances in the Treatment of Schizophrenia
Published online: May 16, 2017
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
https://clinicaltrials.gov/ct2/show/record/NCT01266174
6
